Prostate cancer recurrence, PSADT, and patient comorbidities

D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men with other “comorbid” health problems. … READ MORE …

Prostate cancer news reports: Friday, September 18, 2009

In today’s news reports we have focused primarily on data showing that specific things do not seem to work well in prostate cancer risk assessment and diagnosis:

  • Neither PSA velocity nor the PSA/serum testosterone ratio are normally predictive for risk of prostate cancer in undiagnosed patients.
  • Post-surgical tumor volume is not predictive for risk of prostate cancer progression.
  • A new nomogram predicts risk of pathological upgrading post-surgery. … READ MORE …

The news report: Thursday, April 23, 2009

We have reported separately on a study of the long-term durability of erectile function following brachytherapy using permanent seed implantation. Other reports today address:

  • Literacy levels and prostate cancer communication
  • Antiperspirant use as a possible cause of prostate (and breast) cancer
  • A gene-based tool to predict prostate cancer risk
  • Drugs in development for prostate cancer prevention
  • PSA velocity and prostate cancer diagnosis
  • Identification of good candidates for salvage radical prostatectomy … READ MORE …

PSA velocity pre-biopsy: has Vickers’ hypothesis been proven?

PSA velocity is, at present, included in National Comprehensive Cancer Network guidelines as a potential prognostic factor for need for a prostate biopsy. However, Vickers and colleagues argue that calculation of PSA velocity adds nothing to the ability to predict risk for a diagnosis of prostate cancer on biopsy by comparison with simpler PSA data. … READ MORE …

The Wednesday news update: January 21, 2009

Today’s news includes information on:

  • The use of markers for prognosis following first-line treatment for localized prostate cancer
  • Results of a Phase II trial of neoadjuvant docetaxel + gefitinib prior to radical prostatectomy
  • Results of a Phase III trial of gabapentin in management of ADT-related “hot flashes”
  • MRI-directed HIFU in the treatment of localized prostate cancer … READ MORE …

PSA kinetics and prediction of outcomes of untreated patients

There has been an on-going difference of opinion within sections of the urology community regarding the value of PSA velocity and/or PSA doubling times in predicting outcomes to first-line prostate cancer treatment. … READ MORE …

The Saturday prostate cancer news: November 29, 2008

We have separately addressed a report on 10-year outcome data following (non-robotic) laparoscopic radical prostatectomy for localized prostate cancer. In today’s other reports we have addressed:

  • The potential of annexin A3 as a marker for early diagnosis of prostate cancer
  • The ability of PSAV and PSAD to predict risk for prostate cancer in men with one or more negative prostate biopsies
  • Estrogens, estrogen receptors, and prostate cancer development and progression
  • Differences between clinical and pathological Gleason scores and the impact on outcomes following surgery … READ MORE …